Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 3/20 | 0.40 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25708294 | 0.90 | ADRB3 (0.47) | ADRB3SLC16A3LMNAMEN1KMT2A | |
| SCHEMBL4801268 | 0.90 | ADRB3 (0.47) | ADRB3SLC16A3LMNAMEN1KMT2A | |
| SCHEMBL14357339 | 0.74 | ADRB2 (0.57) | ADRB3LMNAMEN1KMT2AADRB2 | |
| SCHEMBL2829651 | 0.74 | ADRB2 (0.57) | ADRB3LMNAMEN1KMT2AADRB2 | |
| SCHEMBL14357338 | 0.74 | ADRB2 (0.57) | ADRB3LMNAMEN1KMT2AADRB2 | |
| SCHEMBL4801598 | 0.74 | GPR55 (0.32) | ADRB3LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL4801593 | 0.74 | GPR55 (0.32) | ADRB3LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5431193 | 0.74 | ADRB2 (0.45) | ADRB3LMNAADRB2ADRA1DKDM4E | |
| SCHEMBL17660490 | 0.74 | KMT2A (0.39) | ADRB3MEN1KMT2AADRB2ADRA1D | |
| SCHEMBL5391885 | 0.74 | ADRB3 (0.45) | ADRB3ADRB2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180876-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180876-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | ADRB3 128/4885SLC16A3 1150/4885LMNA 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.